Abstract:3002 Background: Tissue factor (TF) overexpression is associated with thrombosis, metastasis and poor prognosis in solid tumors, including cervical and pancreatic cancer. MRG004A is a novel anti-TF monoclonal antibody conjugated (ADC) to MMAE payload (drug-to-antibody ratio: 3.8), utilizing Glycoconnect site-specific conjugation technology. Herein, we present the preliminary safety and efficacy data from phase I/II MRG004A-001. Methods: This is an interim report (Data cutoff: Dec 15, 2023) of first-in-human, dose-escalation and expansion study ongoing in the USA and China. Pts with ECOG 0-1 with unresectable/metastatic solid tumor with measurable disease per RECIST v1.1 that progressed on prior systemic therapy, received MRG004A monotherapy Q3W intravenously. The primary objectives were to assess the safety, activity, maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D). Baseline tissue was evaluated for the association of TF expression with objective response rate (ORR) and disease control rate (DCR). Results: Sixty-three pts were enrolled with 43 in dose-escalation phase (8 dose levels [0.3-2.6mg/kg]) and 20 in dose-expansion phase (15 at 2.0mg/kg and 5 at 2.4mg/kg). Median age 58 (38-75). ECOG0: 8 (13%) pts. Female: 37 (59%) pts. Median 3 prior lines of therapy: 3 (1-10). MTD was not reached. Sixteen baseline samples were evaluated for overall % membrane positivity by immunohistochemistry. Nineteen were pancreatic cancer (PC) and 68% (13/19) had TF ≥50% and 2 or 3 (+). Five received dose <2 mg/kg Q3W. Significant anti-tumor activity of MRG004A was observed in pts with PC. Among 12 evaluable pts with PC in the 2.0mg/kg cohort, who have received median 3 lines of prior therapy, there were 4 PR and 6 SD. ORR was 33.3% (4/12) and DCR was 83.3% (10/12). Among them, 5 pts with PC of TF expression ≥50% and 3+ intensity and ≤2 prior lines of therapy received MRG004A at 2mg/kg. 4 of 5 TF-overexpressed PC achieved PR and 1 SD. Also, MRG004A showed efficacy in other cancers. In 4 pts with heavily-treated triple-negative breast cancer (TNBC), ORR and DCR were 25% (1/4) and 50% (2/4), respectively. In 2 pts with cervical cancer with four prior therapy lines, 1 PR and 1 SD. Common treatment-related adverse events (TRAE) of any grade include conjunctivitis (27%), anemia (17%), and hypoalbuminemia (13%) and 7.9% (5/63) pts had serious adverse events. One pt with TNBC treated at 1.8mg/kg experienced G3 Steven Johnson Syndrome, a dose-limiting toxicity (DLT), but resolved. No other DLT was observed and dose expansion and matured outcome evaluation is ongoing. Conclusions: MRG004A demonstrated a manageable toxicity and a striking antitumor activity across multiple tumor types with high TF expression in heavily pretreated setting, including pancreatic cancers. These encouraging findings warrant further evaluation of MRG004A, particularly in the context of TF-overexpressed solid tumors. Clinical trial information: NCT03941574 .

Phase Ia Study of CBP-1008, a Bi-Specific Ligand Drug Conjugate Targeting FRα and TRPV6, in Patients with Advanced Solid Tumors.

A Phase Ia/Ib Study of CBP-1008, a Bispecific Ligand Drug Conjugate, in Patients with Advanced Solid Tumors

First-in-human, Phase I Study of CBP-1008, a First-in-class Bispecific Ligand Drug Conjugate (Bi-Xdc), in Patients with Advanced Solid Tumors

Abstract 1819: CBP-1008 shows excellent efficacy and desirable drug safety profile in preclinical models

A phase 1, multi-center, open-label, dose-escalation and dose expansion study of CBP-1018, a bi-ligand-drug conjugate, in patients with heavily treated advanced solid tumors.

An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors

Phase 1 Study of BAT8006, a Folate Receptor Α Antibody Drug Conjugate with Strong Bystander Effect, in Subjects with Advanced Solid Tumors.

Phase I Clinical Study of FC084CSA, a High Selective AXL Kinase Inhibitor That Ameliorates Tumor Microenvironment and Augments the Effectivity of Immunotherapy.

A Phase Ia/Ib Trial of the Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mab), CS1001, in Patients (pts) with Advanced Solid Tumours or Lymphomas

Phase 1/2 Study of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Advanced Solid Tumors: Interim Results from Dose-Escalation.

Anti-TNFR2 Monoclonal Antibody LBL-019 in Patients with Advanced Malignant Tumors: A Phase I, First-in-human, Open-Label, Multicenter, Dose Escalation Study.

A phase I study to evaluate the safety, tolerability, and pharmacokinetics of MSB0254 in Chinese patients with solid tumors.

A Phase I Open-Label Study of a Novel IL-2Rβ/γ Cytokine Agonist, LTC004, in Patients with Advanced or Metastatic Solid Tumors.

Phase I/II First-in-human Study to Evaluate the Safety and Efficacy of Tissue Factor-Adc MRG004A in Patients with Solid Tumors.

A Phase Ia/Ib Trial Of The Anti-Pd-L1 Human Monoclonal Antibody (Mab), Cs1001, In Patients (Pts) With Advanced Solid Tumors Or Lymphomas.

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

1036P A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

473P Phase I Study of GFH018, a Small Molecular TGF-βRI Inhibitor, in Patients (pts) with Advanced Solid Tumors

A First-in-human, Phase I, Dose-Escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability of KD6001, a Novel Anti-Ctla-4 Monoclonal Antibody (mab) in Patients with Advanced Solid Tumors.

First-in-human Phase I/II Safety and Preliminary Efficacy of PM1032, a Bispecific Antibody Targeting CLDN18.2 and 4-1BB, in Patients with Advanced Solid Tumors.